A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer

Summary

This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer. Each cycle of treatment will be 4 weeks in length. Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.

Timeline

Start

2005-03

Primary completion

2010-05

Completion

2010-05

Drugs

Indications